| abstract |
REFERS TO SALTS OF N- [2 - ({(3R) -1- [TRANS-4-HYDROXY-4- (6-METOXYPYRIDIN-3-IL) -CYCLOHEXYL] PIRRODILIN-3-IL} AMINO) -2 -OXOETHYL] -3- (TRIFLUOROMETIL) BENZAMIDE OF FORMULA I WHERE SAID SALT IS SELECTED FROM A SALT OF BIS METHANOSULPHONIC ACID, BIS ETHANOSULPHONIC ACID, CAMPHORIC ACID. SUCH SALT MAY BE IN CRYSTALLINE OR ANHYDROUS FORM AND IS CHARACTERIZED BY PRESENTING AN ENDOTHERMAL PEAK OF 166 ° C DETERMINED BY A DIFFERENTIAL SWEEPING CALORIMETRY THERMOGRAM (DSC) AND A DIFFRACTION PATTERN OF X-RAY DUST THAT COMPRENDS 8 X-RAY DUST WITH PICTURE 7 ° to 21.8 °. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION THAT INCLUDES COMBINING THE COMPOUND OF FORMULA I WITH A METHANOSULPHONIUM ACID IN A CRYSTALLIZING SOLVENT THAT INCLUDES WATER, ALCOHOL AND KETONE AND PRECIPITATING SAID SALT FROM SAID CRYSTALIZED SOLVENT. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES SAID SALT AND THAT ACTS AT THE LEVEL OF THE CCR2 CHEMOKIN RECEPTOR, BEING USEFUL IN THE TREATMENT OF RHEUMATOID DISEASES, ATHEROSCLEROSIS, LUPUS, NEUROPATHIC PAIN |